Increased anticoagulant response to low‐molecular‐weight heparin in plasma from patients with advanced cirrhosis
Introduction: Cirrhotic patients may present thrombotic complications that warrant anticoagulant therapy. However, the efficacy of low‐molecular‐weight heparin (LMWH) in this clinical setting is still unclear. Aims/methods: To evaluate the in vitro effect of LMWH on thrombin generation (TG) in cir...
Gespeichert in:
| Veröffentlicht in: | Journal of thrombosis and haemostasis 2012-09, Vol.10 (9), p.1823-1829 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1829 |
|---|---|
| container_issue | 9 |
| container_start_page | 1823 |
| container_title | Journal of thrombosis and haemostasis |
| container_volume | 10 |
| creator | SENZOLO, M. RODRIGUEZ‐Castro, K. I. ROSSETTO, V. RADU, C. GAVASSO, S. CARRARO, P. ZERBINATI, P. SARTORI, M. T. SIMIONI, P. |
| description | Introduction: Cirrhotic patients may present thrombotic complications that warrant anticoagulant therapy. However, the efficacy of low‐molecular‐weight heparin (LMWH) in this clinical setting is still unclear.
Aims/methods: To evaluate the in vitro effect of LMWH on thrombin generation (TG) in cirrhotic patients at different stages of liver disease. Thirty cirrhotics (10 Child Pugh A, 10 Child Pugh B and 10 Child Pugh C), 10 subjects with inherited type 1 antithrombin (AT) defect and 10 healthy controls were studied. TG was determined at baseline and with anti‐Xa levels after the addition of enoxaparin at 0.35 and 0.7 U anti‐Xa mL. The endogenous thrombin potential (ETP) ratio at 0.35 and 0.7 U anti‐Xa mL was obtained by dividing ETP with LMWH by ETP at baseline.
Results: Mean AT levels in all cirrhotic subgroups and in patients with AT deficiency were significantly lower than in controls. The 0.35 ETP ratio was significantly lower in cirrhotic patients than in controls (0.26 ± 0.1 vs. 0.48 ± 0.1, P |
| doi_str_mv | 10.1111/j.1538-7836.2012.04824.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1038071569</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1038071569</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4194-a6b352688fc3bb78320b1a63f54b50df1f1030a52812075b9193089dabd90b243</originalsourceid><addsrcrecordid>eNqNkE1OwzAQhS0EoqVwBeQlmwb_5MdZsEAV0KJKbMrash2ncZXEwU4p7DgCZ-QkOBS6xhrJT5r3ZjQfABCjCId3vYlwQtk0YzSNCMIkQjEjcfR2BMaHxvGfzikdgTPvNwjhPCHoFIwIyTBhGRqDftEqp4XXBRRtb5QV620dFHTad7b1GvYW1nb39fHZ2Fqr0HRB77RZVz2sdCecaWGorha-EbB0toGd6I1uew93pq-gKF5Fq8ICZZyrrDf-HJyUovb64vefgOf7u9VsPl0-PSxmt8upinEeT0UqaUJSxkpFpQw3ESSxSGmZxDJBRYlLjCgSCWGYoCyROc4pYnkhZJEjSWI6AVf7uZ2zL1vte94Yr3QdDtR263mIM5ThJM2Dle2tylnvnS5550wj3Hsw8YE53_ABJx_Q8oE5_2HO30L08nfLVja6OAT_IAfDzd6wM7V-__dg_riaD4p-A4hQk34</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1038071569</pqid></control><display><type>article</type><title>Increased anticoagulant response to low‐molecular‐weight heparin in plasma from patients with advanced cirrhosis</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>SENZOLO, M. ; RODRIGUEZ‐Castro, K. I. ; ROSSETTO, V. ; RADU, C. ; GAVASSO, S. ; CARRARO, P. ; ZERBINATI, P. ; SARTORI, M. T. ; SIMIONI, P.</creator><creatorcontrib>SENZOLO, M. ; RODRIGUEZ‐Castro, K. I. ; ROSSETTO, V. ; RADU, C. ; GAVASSO, S. ; CARRARO, P. ; ZERBINATI, P. ; SARTORI, M. T. ; SIMIONI, P.</creatorcontrib><description>Introduction: Cirrhotic patients may present thrombotic complications that warrant anticoagulant therapy. However, the efficacy of low‐molecular‐weight heparin (LMWH) in this clinical setting is still unclear.
Aims/methods: To evaluate the in vitro effect of LMWH on thrombin generation (TG) in cirrhotic patients at different stages of liver disease. Thirty cirrhotics (10 Child Pugh A, 10 Child Pugh B and 10 Child Pugh C), 10 subjects with inherited type 1 antithrombin (AT) defect and 10 healthy controls were studied. TG was determined at baseline and with anti‐Xa levels after the addition of enoxaparin at 0.35 and 0.7 U anti‐Xa mL. The endogenous thrombin potential (ETP) ratio at 0.35 and 0.7 U anti‐Xa mL was obtained by dividing ETP with LMWH by ETP at baseline.
Results: Mean AT levels in all cirrhotic subgroups and in patients with AT deficiency were significantly lower than in controls. The 0.35 ETP ratio was significantly lower in cirrhotic patients than in controls (0.26 ± 0.1 vs. 0.48 ± 0.1, P < 0.001) and the reduction paralleled the severity of liver disease, in spite of the concomitant decrease in AT and anti‐Xa activity. AT‐deficient subjects showed a significantly increased 0.35 ETP ratio compared with both cirrhotic patients and controls (0.69 ± 1 vs. 0.26 ± 0.1, P < 0.001, and vs. 0.48 ± 0.1, P = 0.04 respectively). LMWH at 0.7 U anti‐Xa mL completely inhibited TG in 9/30 cirrhosis patients with more advanced liver disease (Child Pugh B and C), whereas complete TG abolition was seen in only 1/10 controls.
Conclusions: Cirrhotic patients show an increased response to LMWH, which correlates with the severity of liver disease, in spite of reduced AT and anti‐Xa activity levels. Thrombin generation may be a useful tool to monitor the response to LMWH in cirrhotic patients.</description><identifier>ISSN: 1538-7933</identifier><identifier>ISSN: 1538-7836</identifier><identifier>EISSN: 1538-7836</identifier><identifier>DOI: 10.1111/j.1538-7836.2012.04824.x</identifier><identifier>PMID: 22712870</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Anticoagulants - therapeutic use ; anticoagulation ; antithrombin ; anti‐Xa ; cirrhosis ; Female ; Heparin, Low-Molecular-Weight - blood ; Heparin, Low-Molecular-Weight - therapeutic use ; Humans ; Liver Cirrhosis - drug therapy ; Liver Cirrhosis - physiopathology ; low‐molecular‐weight heparin ; Male ; Middle Aged</subject><ispartof>Journal of thrombosis and haemostasis, 2012-09, Vol.10 (9), p.1823-1829</ispartof><rights>2012 International Society on Thrombosis and Haemostasis</rights><rights>2012 International Society on Thrombosis and Haemostasis.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4194-a6b352688fc3bb78320b1a63f54b50df1f1030a52812075b9193089dabd90b243</citedby><cites>FETCH-LOGICAL-c4194-a6b352688fc3bb78320b1a63f54b50df1f1030a52812075b9193089dabd90b243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22712870$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SENZOLO, M.</creatorcontrib><creatorcontrib>RODRIGUEZ‐Castro, K. I.</creatorcontrib><creatorcontrib>ROSSETTO, V.</creatorcontrib><creatorcontrib>RADU, C.</creatorcontrib><creatorcontrib>GAVASSO, S.</creatorcontrib><creatorcontrib>CARRARO, P.</creatorcontrib><creatorcontrib>ZERBINATI, P.</creatorcontrib><creatorcontrib>SARTORI, M. T.</creatorcontrib><creatorcontrib>SIMIONI, P.</creatorcontrib><title>Increased anticoagulant response to low‐molecular‐weight heparin in plasma from patients with advanced cirrhosis</title><title>Journal of thrombosis and haemostasis</title><addtitle>J Thromb Haemost</addtitle><description>Introduction: Cirrhotic patients may present thrombotic complications that warrant anticoagulant therapy. However, the efficacy of low‐molecular‐weight heparin (LMWH) in this clinical setting is still unclear.
Aims/methods: To evaluate the in vitro effect of LMWH on thrombin generation (TG) in cirrhotic patients at different stages of liver disease. Thirty cirrhotics (10 Child Pugh A, 10 Child Pugh B and 10 Child Pugh C), 10 subjects with inherited type 1 antithrombin (AT) defect and 10 healthy controls were studied. TG was determined at baseline and with anti‐Xa levels after the addition of enoxaparin at 0.35 and 0.7 U anti‐Xa mL. The endogenous thrombin potential (ETP) ratio at 0.35 and 0.7 U anti‐Xa mL was obtained by dividing ETP with LMWH by ETP at baseline.
Results: Mean AT levels in all cirrhotic subgroups and in patients with AT deficiency were significantly lower than in controls. The 0.35 ETP ratio was significantly lower in cirrhotic patients than in controls (0.26 ± 0.1 vs. 0.48 ± 0.1, P < 0.001) and the reduction paralleled the severity of liver disease, in spite of the concomitant decrease in AT and anti‐Xa activity. AT‐deficient subjects showed a significantly increased 0.35 ETP ratio compared with both cirrhotic patients and controls (0.69 ± 1 vs. 0.26 ± 0.1, P < 0.001, and vs. 0.48 ± 0.1, P = 0.04 respectively). LMWH at 0.7 U anti‐Xa mL completely inhibited TG in 9/30 cirrhosis patients with more advanced liver disease (Child Pugh B and C), whereas complete TG abolition was seen in only 1/10 controls.
Conclusions: Cirrhotic patients show an increased response to LMWH, which correlates with the severity of liver disease, in spite of reduced AT and anti‐Xa activity levels. Thrombin generation may be a useful tool to monitor the response to LMWH in cirrhotic patients.</description><subject>Anticoagulants - therapeutic use</subject><subject>anticoagulation</subject><subject>antithrombin</subject><subject>anti‐Xa</subject><subject>cirrhosis</subject><subject>Female</subject><subject>Heparin, Low-Molecular-Weight - blood</subject><subject>Heparin, Low-Molecular-Weight - therapeutic use</subject><subject>Humans</subject><subject>Liver Cirrhosis - drug therapy</subject><subject>Liver Cirrhosis - physiopathology</subject><subject>low‐molecular‐weight heparin</subject><subject>Male</subject><subject>Middle Aged</subject><issn>1538-7933</issn><issn>1538-7836</issn><issn>1538-7836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1OwzAQhS0EoqVwBeQlmwb_5MdZsEAV0KJKbMrash2ncZXEwU4p7DgCZ-QkOBS6xhrJT5r3ZjQfABCjCId3vYlwQtk0YzSNCMIkQjEjcfR2BMaHxvGfzikdgTPvNwjhPCHoFIwIyTBhGRqDftEqp4XXBRRtb5QV620dFHTad7b1GvYW1nb39fHZ2Fqr0HRB77RZVz2sdCecaWGorha-EbB0toGd6I1uew93pq-gKF5Fq8ICZZyrrDf-HJyUovb64vefgOf7u9VsPl0-PSxmt8upinEeT0UqaUJSxkpFpQw3ESSxSGmZxDJBRYlLjCgSCWGYoCyROc4pYnkhZJEjSWI6AVf7uZ2zL1vte94Yr3QdDtR263mIM5ThJM2Dle2tylnvnS5550wj3Hsw8YE53_ABJx_Q8oE5_2HO30L08nfLVja6OAT_IAfDzd6wM7V-__dg_riaD4p-A4hQk34</recordid><startdate>201209</startdate><enddate>201209</enddate><creator>SENZOLO, M.</creator><creator>RODRIGUEZ‐Castro, K. I.</creator><creator>ROSSETTO, V.</creator><creator>RADU, C.</creator><creator>GAVASSO, S.</creator><creator>CARRARO, P.</creator><creator>ZERBINATI, P.</creator><creator>SARTORI, M. T.</creator><creator>SIMIONI, P.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201209</creationdate><title>Increased anticoagulant response to low‐molecular‐weight heparin in plasma from patients with advanced cirrhosis</title><author>SENZOLO, M. ; RODRIGUEZ‐Castro, K. I. ; ROSSETTO, V. ; RADU, C. ; GAVASSO, S. ; CARRARO, P. ; ZERBINATI, P. ; SARTORI, M. T. ; SIMIONI, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4194-a6b352688fc3bb78320b1a63f54b50df1f1030a52812075b9193089dabd90b243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Anticoagulants - therapeutic use</topic><topic>anticoagulation</topic><topic>antithrombin</topic><topic>anti‐Xa</topic><topic>cirrhosis</topic><topic>Female</topic><topic>Heparin, Low-Molecular-Weight - blood</topic><topic>Heparin, Low-Molecular-Weight - therapeutic use</topic><topic>Humans</topic><topic>Liver Cirrhosis - drug therapy</topic><topic>Liver Cirrhosis - physiopathology</topic><topic>low‐molecular‐weight heparin</topic><topic>Male</topic><topic>Middle Aged</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SENZOLO, M.</creatorcontrib><creatorcontrib>RODRIGUEZ‐Castro, K. I.</creatorcontrib><creatorcontrib>ROSSETTO, V.</creatorcontrib><creatorcontrib>RADU, C.</creatorcontrib><creatorcontrib>GAVASSO, S.</creatorcontrib><creatorcontrib>CARRARO, P.</creatorcontrib><creatorcontrib>ZERBINATI, P.</creatorcontrib><creatorcontrib>SARTORI, M. T.</creatorcontrib><creatorcontrib>SIMIONI, P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SENZOLO, M.</au><au>RODRIGUEZ‐Castro, K. I.</au><au>ROSSETTO, V.</au><au>RADU, C.</au><au>GAVASSO, S.</au><au>CARRARO, P.</au><au>ZERBINATI, P.</au><au>SARTORI, M. T.</au><au>SIMIONI, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased anticoagulant response to low‐molecular‐weight heparin in plasma from patients with advanced cirrhosis</atitle><jtitle>Journal of thrombosis and haemostasis</jtitle><addtitle>J Thromb Haemost</addtitle><date>2012-09</date><risdate>2012</risdate><volume>10</volume><issue>9</issue><spage>1823</spage><epage>1829</epage><pages>1823-1829</pages><issn>1538-7933</issn><issn>1538-7836</issn><eissn>1538-7836</eissn><abstract>Introduction: Cirrhotic patients may present thrombotic complications that warrant anticoagulant therapy. However, the efficacy of low‐molecular‐weight heparin (LMWH) in this clinical setting is still unclear.
Aims/methods: To evaluate the in vitro effect of LMWH on thrombin generation (TG) in cirrhotic patients at different stages of liver disease. Thirty cirrhotics (10 Child Pugh A, 10 Child Pugh B and 10 Child Pugh C), 10 subjects with inherited type 1 antithrombin (AT) defect and 10 healthy controls were studied. TG was determined at baseline and with anti‐Xa levels after the addition of enoxaparin at 0.35 and 0.7 U anti‐Xa mL. The endogenous thrombin potential (ETP) ratio at 0.35 and 0.7 U anti‐Xa mL was obtained by dividing ETP with LMWH by ETP at baseline.
Results: Mean AT levels in all cirrhotic subgroups and in patients with AT deficiency were significantly lower than in controls. The 0.35 ETP ratio was significantly lower in cirrhotic patients than in controls (0.26 ± 0.1 vs. 0.48 ± 0.1, P < 0.001) and the reduction paralleled the severity of liver disease, in spite of the concomitant decrease in AT and anti‐Xa activity. AT‐deficient subjects showed a significantly increased 0.35 ETP ratio compared with both cirrhotic patients and controls (0.69 ± 1 vs. 0.26 ± 0.1, P < 0.001, and vs. 0.48 ± 0.1, P = 0.04 respectively). LMWH at 0.7 U anti‐Xa mL completely inhibited TG in 9/30 cirrhosis patients with more advanced liver disease (Child Pugh B and C), whereas complete TG abolition was seen in only 1/10 controls.
Conclusions: Cirrhotic patients show an increased response to LMWH, which correlates with the severity of liver disease, in spite of reduced AT and anti‐Xa activity levels. Thrombin generation may be a useful tool to monitor the response to LMWH in cirrhotic patients.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>22712870</pmid><doi>10.1111/j.1538-7836.2012.04824.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1538-7933 |
| ispartof | Journal of thrombosis and haemostasis, 2012-09, Vol.10 (9), p.1823-1829 |
| issn | 1538-7933 1538-7836 1538-7836 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1038071569 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Anticoagulants - therapeutic use anticoagulation antithrombin anti‐Xa cirrhosis Female Heparin, Low-Molecular-Weight - blood Heparin, Low-Molecular-Weight - therapeutic use Humans Liver Cirrhosis - drug therapy Liver Cirrhosis - physiopathology low‐molecular‐weight heparin Male Middle Aged |
| title | Increased anticoagulant response to low‐molecular‐weight heparin in plasma from patients with advanced cirrhosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T00%3A58%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20anticoagulant%20response%20to%20low%E2%80%90molecular%E2%80%90weight%20heparin%20in%20plasma%20from%20patients%20with%20advanced%20cirrhosis&rft.jtitle=Journal%20of%20thrombosis%20and%20haemostasis&rft.au=SENZOLO,%20M.&rft.date=2012-09&rft.volume=10&rft.issue=9&rft.spage=1823&rft.epage=1829&rft.pages=1823-1829&rft.issn=1538-7933&rft.eissn=1538-7836&rft_id=info:doi/10.1111/j.1538-7836.2012.04824.x&rft_dat=%3Cproquest_cross%3E1038071569%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1038071569&rft_id=info:pmid/22712870&rfr_iscdi=true |